|
|
| Maladies Infectieuses > Etude de marché sectorielle |
| 04-013: Overview of Autoimmune Disease Research |
|
|
|
|
€ 800,00 |
Editeur
: |
BioInformatics |
Langue
: |
Anglais |
Date de publication : |
Juin 2004 |
Taille du document : |
162 |
Autres informations : |
Description , Table des matières |
| |
|
|
|
|
| |
|
Rechercher d'autres rapports et études à commander
Rechercher et commander ici parmi 50.000 études de marché publiées par les principaux instituts d'études internationaux
|
| Rapports privés en relation |
|
Pipeline Insight: HIV - Hold Your Horses
216 pages | Avril 2005 |
IntroductionIn the current antiretroviral landscape, resistance in all three of the established classes is proving to be problematic.
Accordingly, current clinical trials are recruiting treatment-r |
9 120,00 €
|
| |
| |
Pipeline Insight: Hepatitis B - New Kids on the Block
211 pages | Avril 2005 |
IntroductionAccording to the WHO, 350-400 million people are chronically infected with HBV progresses to liver cirrhosis and hepatocellular carcinoma.
Previously HBV has been treated with lamivudin |
9 120,00 €
|
| |
| |
Commercial Perspectives: HIV - Benchmarking Rapid Antiretroviral Uptake
181 pages | Février 2005 |
IntroductionHistorically, HIV antiretrovirals have differed markedly in their speed of market uptake.
Now, to win market share in an already mature market, newly launched products need not only a s |
9 120,00 €
|
| |
| |
Hepatitis C Statistics
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
Stakeholder Insight: Hepatitis B & C - Winning Battles But Not The War
329 pages | Décembre 2004 |
IntroductionAccording to the WHO, 350400 million are chronically infected with HBV and 170200 million with HCV.
Although HBV vaccination and routine screening of donated blood has decreased inciden |
12 160,00 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Commercial Perspectives: HIV - Benchmarking Rapid Antiretroviral Uptake
181 pages | Février 2005 |
IntroductionHistorically, HIV antiretrovirals have differed markedly in their speed of market uptake.
Now, to win market share in an already mature market, newly launched products need not only a s |
9 120,00 €
|
| |
| |
Chinese Markets for Vaccine
269 pages | Mars 2003 |
China's demand for vaccine has grown at a fast pace in the past decade.
In the next five years, both production and demand will continue to grow.
This new study examines China's economic trends, |
2 835,00 €
|
| |
| |
Stakeholder Insight: Hepatitis in China - Liver Let Die?
310 pages | Décembre 2005 |
IntroductionHepatitis is a major health problem in China, which is home to one third of hepatitis B patients and one quarter of hepatitis C patients globally.
HBV vaccination, together with HBV and |
12 920,00 €
|
| |
| |
Gen-Probe Clinical Diagnostic Products for the Detection of Viral Microorganisms
1 pages | Janvier 2006 |
This Database Table is a one-page table of hard-to-find numerical information.
The Database Table is derived from a proprietary source and is meant to simply provide a high-level overview of specif |
80,00 €
|
| |
| |
|
| |
| Autres secteurs en relation |
|
|
|
| |
|
| |
| |
| Présentation de l'étude de marché - Description & Table des matières |
|
| 04-013: Overview of Autoimmune Disease Research |
|
|
This overview will help life science suppliers identify opportunities to expand the placement of their immunological tools and technologies as well as assist in stimulating new product ideas and/or enhancements to existing product lines
|
|
This overview will help life science suppliers identify opportunities to expand the placement of their immunological tools and technologies as well as assist in stimulating new product ideas and/or enhancements to existing product lines
|
|
|
PPLSEN
|
|
|
|
|
